JP2022552881A5 - - Google Patents
Info
- Publication number
- JP2022552881A5 JP2022552881A5 JP2022523519A JP2022523519A JP2022552881A5 JP 2022552881 A5 JP2022552881 A5 JP 2022552881A5 JP 2022523519 A JP2022523519 A JP 2022523519A JP 2022523519 A JP2022523519 A JP 2022523519A JP 2022552881 A5 JP2022552881 A5 JP 2022552881A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- cycle
- approximately
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923955P | 2019-10-21 | 2019-10-21 | |
| US62/923,955 | 2019-10-21 | ||
| US202063011147P | 2020-04-16 | 2020-04-16 | |
| US63/011,147 | 2020-04-16 | ||
| PCT/US2020/056409 WO2021080936A1 (en) | 2019-10-21 | 2020-10-20 | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022552881A JP2022552881A (ja) | 2022-12-20 |
| JP2022552881A5 true JP2022552881A5 (enExample) | 2023-10-20 |
| JP7581345B2 JP7581345B2 (ja) | 2024-11-12 |
Family
ID=73452273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523519A Active JP7581345B2 (ja) | 2019-10-21 | 2020-10-20 | ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを用いて慢性リンパ性白血病を治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11628172B2 (enExample) |
| EP (1) | EP4048279B1 (enExample) |
| JP (1) | JP7581345B2 (enExample) |
| KR (1) | KR20220103953A (enExample) |
| CN (2) | CN115919870B (enExample) |
| AU (1) | AU2020369497C1 (enExample) |
| CA (1) | CA3154510A1 (enExample) |
| CL (1) | CL2022000991A1 (enExample) |
| ES (1) | ES3066029T3 (enExample) |
| IL (1) | IL292265B2 (enExample) |
| MX (1) | MX2022004727A (enExample) |
| WO (1) | WO2021080936A1 (enExample) |
| ZA (1) | ZA202204446B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202600194T1 (it) | 2019-10-21 | 2026-05-12 | Celgene Corp | Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica |
| CA3154504A1 (en) | 2019-10-21 | 2021-04-29 | Maria Soraya Carrancio ANTON | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino )isoindoline-1,3-dione |
| US11628172B2 (en) * | 2019-10-21 | 2023-04-18 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| BR112022007580A2 (pt) | 2019-10-21 | 2022-07-05 | Celgene Corp | Formas sólidas que compreendem (s)-2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolino-1,3-diona e seus sais e composições que compreendem as mesmas e seus usos |
| KR20220103952A (ko) * | 2019-10-21 | 2022-07-25 | 셀진 코포레이션 | (s)-2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온을 포함하는 제약 조성물 및 그의 사용 방법 |
| IL292305A (en) * | 2019-10-21 | 2022-06-01 | Celgene Corp | Methods for the treatment of hematological cancer and the use of associated biomarkers for 2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isodonyl 1,3-discussion |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008033567A1 (en) | 2006-09-15 | 2008-03-20 | Celgene Corporation | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| NZ772688A (en) * | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| CA2907908A1 (en) | 2013-04-02 | 2014-10-09 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| CA2954652A1 (en) | 2014-07-11 | 2016-01-14 | Celgene Corporation | Combination therapy for cancer |
| FI3784663T3 (fi) * | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi |
| AR119715A1 (es) * | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| SMT202600194T1 (it) * | 2019-10-21 | 2026-05-12 | Celgene Corp | Combinazione di composti di 4-amminoisoindolin-1,3-dione sostituiti e di secondi agenti attivi per l'uso nel trattamento di una condizione maligna ematologica |
| CA3154504A1 (en) * | 2019-10-21 | 2021-04-29 | Maria Soraya Carrancio ANTON | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino )isoindoline-1,3-dione |
| US11628172B2 (en) * | 2019-10-21 | 2023-04-18 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| KR20220103952A (ko) * | 2019-10-21 | 2022-07-25 | 셀진 코포레이션 | (s)-2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온을 포함하는 제약 조성물 및 그의 사용 방법 |
| IL292305A (en) * | 2019-10-21 | 2022-06-01 | Celgene Corp | Methods for the treatment of hematological cancer and the use of associated biomarkers for 2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isodonyl 1,3-discussion |
-
2020
- 2020-10-20 US US17/075,125 patent/US11628172B2/en active Active
- 2020-10-20 KR KR1020227016738A patent/KR20220103953A/ko active Pending
- 2020-10-20 MX MX2022004727A patent/MX2022004727A/es unknown
- 2020-10-20 WO PCT/US2020/056409 patent/WO2021080936A1/en not_active Ceased
- 2020-10-20 CA CA3154510A patent/CA3154510A1/en active Pending
- 2020-10-20 EP EP20807936.8A patent/EP4048279B1/en active Active
- 2020-10-20 AU AU2020369497A patent/AU2020369497C1/en active Active
- 2020-10-20 IL IL292265A patent/IL292265B2/en unknown
- 2020-10-20 ES ES20807936T patent/ES3066029T3/es active Active
- 2020-10-20 CN CN202310077726.4A patent/CN115919870B/zh active Active
- 2020-10-20 CN CN202080088934.9A patent/CN114885603A/zh active Pending
- 2020-10-20 JP JP2022523519A patent/JP7581345B2/ja active Active
-
2022
- 2022-04-20 CL CL2022000991A patent/CL2022000991A1/es unknown
- 2022-04-20 ZA ZA2022/04446A patent/ZA202204446B/en unknown
-
2023
- 2023-03-09 US US18/119,679 patent/US20230210859A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527398A5 (enExample) | ||
| JP2021155426A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2008515905A5 (enExample) | ||
| JP2020505423A5 (enExample) | ||
| JP2008521827A5 (enExample) | ||
| US9238033B2 (en) | Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine | |
| IL292265B1 (en) | Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione) | |
| SK112001A3 (en) | Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug | |
| US8492383B2 (en) | Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia | |
| TW201822769A (zh) | 用於治療非小細胞肺癌之egfr t790m 抑制劑及cdk抑制劑之組合 | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| JPWO2023054732A5 (enExample) | ||
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| JP7151029B2 (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| JPWO2020175629A5 (enExample) | ||
| JP2024531188A5 (enExample) | ||
| JP2024095711A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| JP2006515004A5 (enExample) | ||
| JP2019218379A5 (enExample) | ||
| JP2023549849A5 (enExample) | ||
| JP2023553253A5 (enExample) | ||
| JP2023548429A5 (enExample) | ||
| CN100506224C (zh) | 包含选择性环加氧酶-2抑制剂的组合 |